Last reviewed · How we verify

NCT03410940

PMCF Study of the CLS Brevius Stem With Kinectiv Technology

Terminated Last updated 17 December 2020
What this trial tests

trial testing CLS Brevius stem with Kinectiv technology in Osteoarthritis in 223 participants. Terminated before completion.

Timeline
7 January 2011
Primary endpoint
8 April 2019
14 December 2020

Quick facts

Lead sponsorZimmer Biomet
StatusTerminated
Study typeOBSERVATIONAL
Enrollment223
Start date7 January 2011
Primary completion8 April 2019
Estimated completion14 December 2020
Sites4 locations across Italy, Spain, Poland

Drugs / interventions tested

Conditions studied

Sponsor

Zimmer Biomet — full company profile →

Who can join

18 and older, any sex, with Osteoarthritis or Avascular Necrosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a multi-center, prospective, non-controlled post-market surveillance study. The primary objective of this study is to confirm the safety and performance of the CLS Brevius stem with Kinectiv technology by obtaining implant survivorship and clinical outcomes data for the commercially available stem.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Satisfactory clinical and radiologic outcomes with a new shorter and modular stem for end-stage hip osteoarthritis: an international prospective multicentre pilot study.
    D'Ambrosi R, Toni A, Czubak J, Guadilla J, et al · · 2022 · cited 1× · PMID 35380533 · DOI 10.1051/sicotj/2022005

Verify or expand the search:

Other recruiting trials for Osteoarthritis

Currently open trials in the same condition.

Other Zimmer Biomet trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03410940.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing